Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05722522 |
Recruitment Status :
Recruiting
First Posted : February 10, 2023
Last Update Posted : April 16, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rotator Cuff Tendinopathy | Drug: Secukinumab Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 234 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Investigator, site personnel, persons performing the assessments and participants will remain blinded through the Week 24 final database lock. The Novartis clinical trial and submission teams will remain blinded to the identity of the treatment from the time of randomization until the Week 16 database lock (for the primary endpoint analysis). The following methods are utilized for blinding: (1) Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by anyone else involved in the study with the following exceptions: bioanalyst; (2) the identity of the treatments will be concealed by the use of study treatments that are all identical in packaging, labeling, schedule of administration, and appearance. |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy |
Actual Study Start Date : | August 10, 2023 |
Estimated Primary Completion Date : | November 28, 2024 |
Estimated Study Completion Date : | January 23, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Secukinumab
|
Drug: Secukinumab
The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Other Name: AIN457 |
Placebo Comparator: Placebo
|
Drug: Placebo
The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12 |
- Change from BSL in in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) score [ Time Frame: At Week 16 ]
Improving physical shoulder symptoms in participants with moderate to severe RCT at Week 16
The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with RCT relating to pain, weakness, stiffness, and mechanical symptoms. A score of 0 is the best outcome in terms of physical symptoms and a score of 60 is the worst possible score
- Proportion of participants who achieve an improvement (increase) of at least 40 points from BSL in the WORC PSD [ Time Frame: At Week 16 ]Achieving a clinically meaningful response in improving physical shoulder symptoms in participants with moderate to severe RCT at Week 16
- Proportion of participants who achieve an improvement (increase) of at least 50 points from BSL in the WORC total score [ Time Frame: At Week 16 ]Improving symptoms caused by RCT and the associated impact on day-to-day functioning in participants with moderate to severe RCT at Week 16
- Change from BSL in the Patient-Reported Outcomes Measurement Information System (PROMIS) - Short Form (SF) Upper Extremity score [ Time Frame: At Week 16 ]
Improving physical function in participants with moderate to severe RCT at Week 16.
PROMIS-SF Upper Extremity measures self-reported capability of Physical Function. Participants will be asked a series of 7 questions rating their ability to perform a range of physical activities related to daily life that would be impacted by shoulder function. Each response is scored from 5 (Without any difficulty) to 1 (Unable to do)
- Proportion of participants who achieve an improvement (increase) of at least 40 points from BSL in the WORC PSD. Change from BSL in the WORC PSD score [ Time Frame: At Week 24 ]Improvement of physical symptoms at Week 24
- Secukinumab serum concentrations [ Time Frame: Day 1 and Weeks 4 and 16 ]Pharmacokinetic parameters (measures of treatment exposure) will be evaluated in all participants, with moderate to severe RCT, treated with secukinumab 300 mg s.c.
- Safety and tolerability of secukinumab [ Time Frame: Up to Week 24 ]Evaluate safety and tolerability of 300 mg s.c. secukinumab, in participants with moderate to severe RCT: Adverse Events and Serious Adverse Events (incidence, severity, and relationship with study drug), incidence of clinically significant changes in laboratory parameters and vital signs
- Incidence of binding and neutralizing Anti-drug antibodies [ Time Frame: At Day 1 and Week 16 ]Evaluate immunogenicity of 300 mg s.c. secukinumab, in participants with moderate to severe RCT
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Unilateral rotator cuff tendinopathy with ≥ 6 weeks to ≤ 6 months symptom duration at BSL.
- Nocturnal pain in shoulder on at least 3 out of 7 nights in the week prior to Baseline or "positive painful arc test" on examination.
- Total WORC percentage score ≤ 40 at the Screening and Baseline visits.
- Average weekly (i.e., the average of the 7 scores taken once a day) numerical rating scale (NRS) pain score of ≥5 during the past 7 days prior to the Baseline visit.
- Refractory to standard of care: NSAIDs course as per local standard practice (if not intolerant or contraindicated) and a course of physiotherapy over a period of 8 weeks.
- Participant must agree to remain on stable NSAID dosage regimen (if not intolerant or having contraindications; NSAID dose is permitted to be reduced, but not increased above dose established at run-in) and physiotherapy regimen from run-in period until End of Study (EOS).
- Presence of tendinopathy in the affected shoulder on a centrally read MRI (Magnetic Resonance Imaging), with the following conditions: with no tear or partial tear (maximum 50% tendon thickness; AP length maximum 10 mm)
Exclusion Criteria:
- Rheumatological and non-rheumatological inflammatory diseases, including but not limited to polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), axial spondyloarthritis (AS: Ankylosing Spondylitis, nr-axSpA: non-radiographic Axial Spondyloarthritis), psoriasis (PsO), and rheumatoid arthritis (RA); fibromyalgia or severe pain disorder unrelated to the target shoulder; gout; and systemic lupus erythematosus.
- Rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies positive at Screening.
- Oral, intramuscular or intravenous (i.v.) corticosteroid treatment within the last 12 weeks prior to randomization, or presence of any condition that might require intermittent corticosteroid use.
- Lack of compliance with adhering to NSAID (unless intolerant or contraindicated) and physiotherapy regimen during run-in period.
- Positive painful arc test result in contralateral shoulder
- Inability or unwillingness to undergo MRI of the shoulder (e.g., participants with pacemakers, or metal fragments/foreign objects in the body that are not compatible with performing an MRI) to fulfill eligibility criteria (unless centrally read MRI images acquired within 3 months of Baseline can be provided and the quality of images is deemed sufficient).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05722522
Contact: Novartis Pharmaceuticals | 1-888-669-6682 | novartis.email@novartis.com | |
Contact: Novartis Pharmaceuticals | +41613241111 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT05722522 |
Other Study ID Numbers: |
CAIN457O12301 2021-002038-18 ( EudraCT Number ) |
First Posted: | February 10, 2023 Key Record Dates |
Last Update Posted: | April 16, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Moderate to Severe Rotator Cuff Tendinopathy Adult Unilateral Refractory to standard of care |
Tendinopathy Muscular Diseases Musculoskeletal Diseases Tendon Injuries Wounds and Injuries |